Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results , with sales up 6% year on ...

Stifel Nicolaus analyst Annabel Samimy maintained a Hold rating on Supernus Pharmaceuticals (SUPN – Research Report) today and set a price ...

Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of ...

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results tomorrow after ...

The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Supernus (SUPN) delivered earnings and revenue surprises of 44.23% and 12.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...

Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...

(SUPN) on Tuesday reported fourth-quarter earnings of $15.3 million. On a per-share basis, the Rockville, Maryland-based company said it had net income of 27 cents. Earnings, adjusted for amortization ...

Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...

Supernus' SPN-820 failed to show significant improvement in depression severity in its Phase 2b study, with no difference from placebo. The safety profile of SPN-820 remained consistent with ...

The biopharmaceutical firm, focused on developing treatments for central nervous system diseases, posted Q4 revenue of $174.2 million, surpassing the analyst consensus of $150.24 million. However, ...